Monographie - Tigecycline - Stabilis 4.0

Poslední aktualizace :
19/11/2024

Antibiotikum

Tigecycline

injekce

Stabilita roztoků

Stabilita směsí

Faktory ovlivňující stabilitu

Kompatibilita

Způsoby aplikace

Odkazy

pdf

Chemický vzorec

Obchodní název

Obchodní název

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eticina	Mexiko
Grexyl	Mexiko
Linicetil	Mexiko
Mrsacin	Turecko
Tecygen	Chile
Tigecid	Turecko
Tigecilina	Argentina, Chile, Ekvádor
Tigecycline	Kanada
Tigetop	Chile
Tizoxim	Argentina
Tygacil	äpanÏlsko, Argentina, Belgie, Chile, Dánsko, Ekvádor, Finsko, Francie, Irsko, Island, Itálie, Japonsko, Kanada, Kolumbie, Lucembursko, Malajsie, MaÔarsko, Mexiko, NÏmecko, Nizozemsko, Norsko, nový Zéland, Peru, Polsko, Portugalsko, Rakousko, Rumunsko, Saúdská Arábie, Spojené arabské emiráty, Švédsko, Švýcarsko, Turecko, USA, Velká Británie, Venezuela, ÿecko
Zomiprerin	Peru

Odkazy

injekce

Odkazy : Tigecycline

	typ	uveřejnění
2262	noviny	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Laboratoř	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	noviny	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratoř	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Laboratoř	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Laboratoř	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laboratoř	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	plakát	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	plakát	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakát	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	noviny	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	noviny	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	noviny	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	noviny	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	noviny	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales